Targets › MIF
1 program from 1 company in 2 trials: 2 Phase 1; Oncology, Other; next expected readout Jan 2027.
Pro-inflammatory cytokine involved in the innate immune response to bacterial pathogens. The expression of MIF at sites of inflammation suggests a role as mediator in regulating the function of macrophages in host defense. (UniProt, P14174)
Open in Phaseline: the race on MIF, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Nanjing Immunophage Biotech | IPG1094 Macrophage migration inhibitory factor (MIF) inhibitor | MIF | Phase 1 | Healthy Volunteers; Solid Tumor | Jan 2027 |
Healthy Volunteers (1) Solid Tumor (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.